Your browser doesn't support javascript.
loading
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He, Wenwu; Leng, Xuefeng; Mao, Tianqin; Luo, Xi; Zhou, Lingxiao; Yan, Jiaxin; Peng, Lin; Fang, Qiang; Liu, Guangyuan; Wei, Xing; Wang, Kangning; Wang, Chenghao; Zhang, Sha; Zhang, Xudong; Shen, Xudong; Huang, Depei; Yi, Huan; Bei, Ting; She, Xueke; Xiao, Wenguang; Han, Yongtao.
Affiliation
  • He W; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Leng X; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Mao T; School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Luo X; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Zhou L; Department of Endoscopy Center, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Yan J; Department of Pathology, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Peng L; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Fang Q; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Liu G; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Wei X; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Wang K; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Wang C; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Zhang S; Department of Endoscopy Center, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Zhang X; Department of Drug Clinical Trial, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Shen X; The Medical Department, 3D Medicines Inc., Shanghai, People's Republic of China.
  • Huang D; The Medical Department, 3D Medicines Inc., Shanghai, People's Republic of China.
  • Yi H; The Medical Department, 3D Medicines Inc., Shanghai, People's Republic of China.
  • Bei T; The Medical Department, 3D Medicines Inc., Shanghai, People's Republic of China.
  • She X; Shanghai Junshi Biosciences Co., Ltd, Shanghai, People's Republic of China.
  • Xiao W; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
  • Han Y; Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, People's Republic of China.
Oncologist ; 27(1): e18-e28, 2022 02 03.
Article de En | MEDLINE | ID: mdl-35305102
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'oesophage / Carcinome épidermoïde de l'oesophage Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2022 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'oesophage / Carcinome épidermoïde de l'oesophage Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2022 Type de document: Article Pays de publication: Royaume-Uni